timothy sykes logo
PLTR Stock Wobbles As NHS Critique And RBC Undercut AI Hype Thumbnail
G Google News

PLTR Stock Wobbles As NHS Critique And RBC Undercut AI Hype

TIM SYKES•UPDATED AUG. 6, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Palantir Technologies Inc. stocks have been trading down by -2.8 percent amid cautious sentiment on slowing government contract momentum.

Key Takeaways

  • A Health Foundation analysis cited by the Financial Times reports that Palantir’s patient discharge tracking software has shown no measurable impact on reducing NHS discharge delays, contradicting Palantir’s prior claims of a 15% reduction.
  • Internal NHS documents call for more rigorous evaluation of Palantir’s discharge tracking software and note that lawmakers are urging use of a 2027 contract break clause to consider replacing Palantir as the software provider.
  • Despite the critical NHS findings, Palantir shares were up more than 2% in pre-market trading after the report was cited by the Financial Times.
  • RBC Capital Markets reiterates an Underperform rating and a $90 price target on Palantir, citing unattractive valuation and concerns about the durability of commercial growth as some clients reassess their relationships amid rising competition.
  • RBC acknowledges some Q2 contract value improvement for Palantir but maintains skepticism about the sustainability of that momentum.

Candlestick Chart

Live Update At 09:18:46 EDT: On Thursday, August 06, 2026 Palantir Technologies Inc. stock [NASDAQ: PLTR] is trending down by -2.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PLTR has been in full-on momentum mode on the chart. Over the last few weeks, Palantir Technologies Inc. pushed from a close near 130 to as high as 166, before slipping back toward the mid‑150s. That kind of parabolic grind higher tells traders one thing: this is a crowded momentum trade, not a sleepy value play.

Daily candles show PLTR repeatedly gapping and extending before sharp intraday reversals. The move from 145.15 to a 164.52 high on 2026/08/04, followed by a red close on 2026/08/05, is classic exhaustion behavior. Intraday, the 5‑minute data around 156–157 shows tight ranges and heavy churn — signs of serious two‑sided trading as late longs battle early shorts.

More Breaking News

Under the hood, Palantir is wildly profitable on paper. Q2 2026 revenue was about $1.94B with an 84.1% gross margin and EBIT margin just over 40%. PLTR is throwing off roughly $1.2B in quarterly free cash flow and running with almost no debt, plus a current ratio near 6.9. But traders can’t ignore valuation: a P/E above 180 and price‑to‑sales north of 70 mean expectations are sky‑high. Any crack in the growth or contract story can hit a name priced like this very hard.

Why Traders Are Watching PLTR So Closely

PLTR is back in the spotlight for all the wrong reasons. The Health Foundation analysis, cited by the Financial Times, says Palantir’s patient discharge tracking software has shown no measurable impact on cutting discharge delays in the UK’s NHS. That directly challenges PLTR’s earlier claim of a 15% reduction. For a data‑driven company that sells “outcomes,” that’s not a small dispute.

The risk is bigger than one metric. Internal NHS documents reportedly push for tougher evaluation and even point out that lawmakers want the NHS to consider using a 2027 break clause to reassess Palantir as the software provider. For PLTR, that means long‑dated government revenue — the kind Wall Street loves to model as steady — is no longer as secure as the bull story suggests.

Yet, in the near term, traders shrugged. After the negative NHS headlines, PLTR was still up more than 2% in pre‑market trading on 2026/07/27. That tells you sentiment is still driven by broad AI enthusiasm and the “must‑own” narrative around Palantir Technologies Inc., more than by contract‑level execution.

Then RBC Capital Markets stepped in with a cold bucket of water. The firm reiterated its Underperform rating and a $90 target on PLTR, flagging what it sees as an unattractive valuation and real questions about commercial growth durability as some clients reassess amid tougher competition. RBC does concede Q2 contract value improved, but the message is clear: they see that as a blip, not a new baseline. For short‑term traders, this creates a classic setup — strong chart, hot story, but cracks appearing in both fundamentals and perception.

Conclusion

For active traders, PLTR is a textbook high‑beta AI name where story, numbers, and price are colliding. On one side, Palantir Technologies Inc. is printing strong margins, high returns on capital, and big free cash flow. The balance sheet is clean, and cash sits above $2.0B. On the other side, the stock trades at nosebleed multiples, and now the NHS story raises doubts about whether flagship deployments are actually delivering what PLTR has promised.

The NHS review and 2027 break‑clause chatter introduce tangible reputational and revenue risk in a marquee public‑sector account. Combine that with RBC sticking to an Underperform and a $90 target while PLTR trades far above that level, and you get a wide expectation gap between bulls and skeptics. Wide gaps like this often resolve with violent moves, not gentle drifts.

For traders, that’s the real edge here. PLTR has the liquidity, volatility, and narrative tension that day and swing traders hunt every day. As Tim Sykes likes to remind his students, “The market doesn’t care about your opinions, only your risk management — cut losses quickly and let the best setups come to you.” As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. With Palantir Technologies Inc., the setup is clear: a loved AI leader facing rising scrutiny. The key now is to respect the risk, watch the levels, and let the chart confirm what the headlines only hint at.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”